Hereditary Hyperbilirubinaemias — Gilbert, Crigler-Najjar, Dubin-Johnson and Rotor

Bilirubin handling involves uptake into the hepatocyte, intracellular processing, conjugation and transport into bile. Heme breakdown produces unconjugated bilirubin, which circulates largely bound to albumin. Within the hepatocyte, UGT1A1 conjugates bilirubin with glucuronic acid, making it water soluble. The conjugated pigment then needs functional transport pathways to be cleared into bile rather than accumulate in blood.

This sequence explains the principal division of hereditary syndromes. A deficient conjugating enzyme leaves an excess of unconjugated, or indirect, bilirubin. Impaired handling of bilirubin after conjugation produces predominantly conjugated, or direct, hyperbilirubinaemia. The bilirubin fraction localizes the problem before the gene name does. Serum bilirubin alone does not establish either liver injury or biliary obstruction.

Use the names as a pathway map: Gilbert and Crigler-Najjar belong to the UGT1A1 group; Dubin-Johnson and Rotor belong to the transport group. The enzyme-deficiency group spans a mild benign phenotype to severe neonatal disease. The transport group usually causes benign jaundice, but the mechanism and liver pigmentation differ. Knowing the location of the defect makes the comparison table easier to reconstruct.

These syndromes are generally described as autosomal recessive. For Gilbert syndrome, genotype and clinical expression vary between populations, so a single promoter variant is not a universal explanation. For Rotor syndrome, the modern mechanistic answer names the uptake transporters and their genes rather than simply saying storage disease. That older shorthand describes impaired hepatocellular handling but does not identify the transport defect.

Avoid sorting the conditions by an isolated bilirubin number without context. Values fluctuate with illness and other triggers, and there is overlap between syndromes. Age at presentation, fraction, severity, enzyme or transporter mechanism, normality of other tests and distinctive urine findings are more useful together. The table is a diagnostic framework, not permission to diagnose every mild jaundice as an inherited disorder.

Gilbert syndrome is a benign disorder of reduced bilirubin glucuronidation. A typical vignette describes a well adolescent or adult with intermittent mild jaundice during fasting, intercurrent illness, dehydration or exertion. The bilirubin elevation is predominantly unconjugated, while other liver biochemical tests are normal. There is no progressive liver failure attributable to Gilbert syndrome.

StatPearls describes a serum total bilirubin below 4 mg/dL, with fluctuation according to triggers. This is a typical pattern rather than an absolute rule for every clinical circumstance. The blood count, reticulocyte count, lactate dehydrogenase and smear are characteristically normal, supporting the absence of haemolysis. Normal aminotransferases and alkaline phosphatase help separate isolated bilirubin handling from hepatocellular or cholestatic disease.

Diagnosis involves excluding other causes when the history or laboratory pattern warrants it. Routine liver biopsy is unnecessary in the usual presentation. Genetic testing can be considered in uncertainty or selected drug-related contexts, but genotype alone should not be treated as a universally definitive diagnostic test. Deliberately fasting a patient to provoke jaundice is not necessary for ordinary clinical diagnosis.

Management is reassurance and education about the benign course and possible triggers. No bilirubin-lowering treatment is routinely needed. A useful pharmacology connection is irinotecan: impaired UGT1A1-mediated handling can increase exposure to its active metabolite and the risk of toxicity. This association is relevant to prescribing, but it does not mean that every medicine is unsafe in every patient with Gilbert syndrome.

Crigler-Najjar syndrome is caused by a major reduction in, or absence of, bilirubin-conjugating UGT activity. Type I has absent or nearly absent enzyme function and can produce severe jaundice soon after birth. Type II retains enzyme activity and usually has a milder course. Both cause nonhaemolytic unconjugated hyperbilirubinaemia; normal red-cell survival does not protect against the consequences of impaired conjugation.

The drug-response distinction follows the enzyme biology. Phenobarbital induces residual UGT activity. In type II there is enzyme capacity to induce, so bilirubin falls. In type I an inducer cannot restore an effectively absent functional pathway. An exam question may describe persistent severe indirect jaundice despite phenobarbital and ask for either the syndrome or the reason for nonresponse.

Do not describe type II as completely free of neurological risk. Severe exacerbations can still cause bilirubin encephalopathy, particularly in stressful clinical circumstances. Likewise, type I does not become benign because a child survives the initial neonatal period. Ongoing bilirubin control is needed while a definitive specialist plan is pursued.

Bilirubin circulates largely bound to albumin. The unbound unconjugated fraction can cross the blood–brain barrier and interact with neural tissue. In severe UGT deficiency, conjugation and clearance fail, increasing the risk of bilirubin encephalopathy. The dangerous species is not simply all bilirubin measured in the serum; protein binding and the clinical circumstances also affect risk.

Kernicterus describes chronic bilirubin-related neurological injury. In a child with severe hereditary unconjugated hyperbilirubinaemia, neurological symptoms require urgent evaluation. Avoid applying an adult jaundice heuristic to a severely jaundiced newborn. Conversely, the very high-risk type I phenotype should not be casually transferred to an otherwise well adult with mild Gilbert syndrome.

Type I management includes intensive phototherapy to control bilirubin and prevent neurological injury. Phototherapy helps reduce the unconjugated bilirubin burden without requiring restoration of the missing enzyme. Liver transplantation provides functional hepatic UGT activity and is the definitive treatment for type I. Specialist measures may be needed during acute crises, with treatment guided by the patient’s condition.

The exam distinction between temporary control and definitive correction is useful: phototherapy controls the bilirubin burden, while a functioning transplanted liver corrects the hepatic conjugation capacity. Phenobarbital is not the definitive answer for type I. For type II, whether medication is necessary depends on the severity and clinical effect rather than on the mere presence of a genetic diagnosis.

Dubin-Johnson syndrome is a disorder of canalicular transport of conjugated bilirubin. The relevant gene is ABCC2, which encodes MRP2, an ATP-binding cassette transporter. Dysfunction impairs secretion of conjugated bilirubin from the hepatocyte into the bile pathway. Because the pigment has already been conjugated, the serum abnormality is predominantly direct hyperbilirubinaemia.

The classic pathology clue is a dark or black liver. Coarsely granular pigment accumulates in centrilobular hepatocytes, while the underlying architecture is usually preserved. The pigment is described as melanin-like on histochemical grounds. Avoid labelling it iron overload or treating the dark appearance as proof of cirrhosis. Pigment is a distinguishing clue, not a reason to perform routine invasive biopsy.

The usual laboratory picture is isolated conjugated bilirubin elevation with otherwise normal liver tests and no evidence of haemolysis. Urinary coproporphyrin analysis gives another discriminator: the total urinary coproporphyrin content is normal, but more than 80% is isomer I. This contrasts with Rotor, where the total excretion is increased and the isomer distribution differs.

The condition is generally benign and does not require routine specific treatment. Diagnosis should fit the clinical and laboratory context. A patient with pain, fever, marked enzyme elevation, impaired synthetic function or an abnormal biliary study requires investigation for another process rather than attribution of every symptom to a benign inherited transporter defect.

Rotor syndrome results from combined deficiency of the organic anion transporting polypeptides OATP1B1 and OATP1B3, encoded by SLCO1B1 and SLCO1B3. These are involved in hepatocellular uptake and reuptake of compounds including bilirubin glucuronides. Impaired uptake, reuptake and storage allow conjugated bilirubin to accumulate in plasma. The principal comparison is with Dubin-Johnson rather than with UGT deficiency.

Rotor causes predominantly conjugated hyperbilirubinaemia, sometimes with a mixed direct and indirect pattern. The liver does not have the characteristic dark pigment of Dubin-Johnson; if a biopsy is performed, histology is normal. As with other benign isolated hyperbilirubinaemias, markedly abnormal liver enzymes or other concerning findings should prompt investigation for an alternative diagnosis.

The two urine findings must be read together: total amount and isomer distribution. Merely saying coproporphyrin I is increased does not fully distinguish the syndromes. The characteristic patterns help support diagnosis while avoiding unnecessary biopsy. Rotor is also generally benign and does not need a treatment aimed simply at normalizing an incidental bilirubin result.

First determine whether the bilirubin is predominantly unconjugated or conjugated. Then decide whether the elevation is truly isolated. The history and examination should check age at onset, illness or fasting triggers, family history, medications, systemic symptoms and neurological concerns. The laboratory pattern should be considered alongside evidence of haemolysis, hepatocellular injury, cholestasis and synthetic dysfunction.

• Mild recurrent indirect jaundice with normal accompanying tests suggests Gilbert after relevant exclusions.
• Severe early indirect jaundice suggests major conjugation deficiency and requires urgent specialist evaluation.
• A fall with phenobarbital supports residual enzyme activity in Crigler-Najjar II.
• Direct-predominant isolated jaundice suggests a transporter syndrome only after competing causes are considered.
• Dark hepatic pigment and the characteristic isomer I predominance support Dubin-Johnson.
• Absent pigment with increased total urinary coproporphyrins supports Rotor.

A useful trap is confusing a benign transporter syndrome with obstruction just because bilirubin is conjugated. Another is diagnosing Gilbert while ignoring anaemia or evidence of haemolysis. The inherited diagnosis should explain the pattern; it should not suppress investigation of findings it cannot explain. No routine biopsy, provocative fasting test or elaborate scan is required merely to memorize the comparison.